South San Francisco, California

Salt River Project Teams with Accenture to Transform the Employee Experience with New Cloud and Digital Capabilities

Retrieved on: 
Wednesday, August 4, 2021
Professional Services, Data Management, Technology, Human Resources, Software, Networks, Consulting, Computing, Business, Companies, SAP SuccessFactors, South San Francisco, California, Cloud infrastructure, SAP, Accenture, Cloud computing, Salt River Project, Accenture, SALT RIVER PROJECT, ACCENTURE

Accenture (NYSE: ACN) has helped Salt River Project (SRP), one of the nations largest public utilities, consolidate its human resources (HR) systems into an integrated cloud-first solution to enhance the employee experience.

Key Points: 
  • Accenture (NYSE: ACN) has helped Salt River Project (SRP), one of the nations largest public utilities, consolidate its human resources (HR) systems into an integrated cloud-first solution to enhance the employee experience.
  • Hosted in the cloud and powered by SAP SuccessFactors software, the new solution replaced disparate legacy HR systems and processes with digital capabilities for employee self-service, payroll, taxes, auditing, compliance, vacation, and time management.
  • Accentures breadth of cloud-first and pre-built configuration, coupled with their change management capabilities and utilities industry expertise, made them the right choice for this program.
  • Accenture is a global professional services company with leading capabilities in digital, cloud and security.

Explora BioLabs Opens New Facility in San Carlos, Calif.

Retrieved on: 
Thursday, July 29, 2021
Geography of California, California, Domes, Explora, San Francisco, San Jose, California, Alameda, California, San Diego, South San Francisco, California

SAN CARLOS, Calif., July 29, 2021 /PRNewswire/ -- Explora BioLabs , a national provider of industry-leading preclinical vivarium research space and management services based in San Diego, opened a new facility in the San Francisco Bay region on July 26, 2021.

Key Points: 
  • SAN CARLOS, Calif., July 29, 2021 /PRNewswire/ -- Explora BioLabs , a national provider of industry-leading preclinical vivarium research space and management services based in San Diego, opened a new facility in the San Francisco Bay region on July 26, 2021.
  • The facility, located in San Carlos between San Francisco and San Jose, joins other Explora BioLabs facilities in the region that opened recently or are planned to open (an Alameda location opened in May, and two South San Francisco facilities will open by December 2021).
  • The facility allows researchers to focus on their science while Explora BioLabs' staff handles the preclinical in vivo management, husbandry, logistics, and compliance requirements.
  • Other facilities in Explora BioLabs' national network are spread throughout San Francisco, San Diego, Calif., and Boston, Mass.

Zipline Raises $250 Million to Scale World’s Largest Automated On-Demand Delivery Service

Retrieved on: 
Wednesday, June 30, 2021
Emerging technologies, Unmanned aerial vehicles, South San Francisco, California, Zipline, Keller Rinaudo, Businesspeople, Technology, Science and technology

Zipline designs, manufactures and operates the worlds largest automated on-demand delivery service.

Key Points: 
  • Zipline designs, manufactures and operates the worlds largest automated on-demand delivery service.
  • The new financing will enable Zipline to continue advancing its integrated service, including its autonomy platform, aircraft, fulfillment systems, and operations.
  • Around the world, our partners are reimagining how patients access care with fast, reliable on-demand delivery, said Keller Rinaudo, founder and CEO at Zipline.
  • We design, manufacture and operate the worlds largest automated on-demand delivery service, which to date has made more than 150,000 commercial deliveries.

Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Retrieved on: 
Thursday, June 17, 2021
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Companies, Genentech, Hoffmann-La Roche, South San Francisco, California, Advisory board, Sab, Life sciences, Industry economics)

Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB).

Key Points: 
  • Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB).
  • New Directors on the Atomwise Board include:
    Mike Varney, who was most recently head of Genentech's Research and Early Development and a member of the Roche Executive Committee.
  • Collectively, these new appointees to the Board of Directors will bring deep expertise in technology, drug discovery, and corporate leadership to advise Atomwise on its business growth.
  • Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.

Sutro Biopharma to Participate in Two Virtual Investor Conferences in June

Retrieved on: 
Tuesday, June 15, 2021
South San Francisco, California, Sutro Biopharma, Sutro, Webcast, Telecommunications, Mass media, Service industries

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company's website at www.sutrobio.com .

Key Points: 
  • Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company's website at www.sutrobio.com .
  • Archived replays of the webcasts will be available on the company's website for approximately 30 days following each live presentation.
  • Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.
  • Follow Sutro on Twitter, @Sutrobio , and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Retrieved on: 
Friday, June 11, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Drugs, Health care, Orphan drugs, Breakthrough therapy, Antineoplastic drugs, Genentech, Hoffmann-La Roche, South San Francisco, California, Venetoclax, Chronic lymphocytic leukemia, Rituximab, the CLL14 Study, the MURANO Study, the VIALE-A Study, Venclexta, Genentech in Hematology, Genentech, THE CLL14 STUDY, THE MURANO STUDY, THE VIALE-A STUDY, VENCLEXTA, GENENTECH IN HEMATOLOGY, GENENTECH

The CLL14 study is being conducted in cooperation with the German CLL Study Group, headed by Michael Hallek, M.D., University of Cologne.

Key Points: 
  • The CLL14 study is being conducted in cooperation with the German CLL Study Group, headed by Michael Hallek, M.D., University of Cologne.
  • Following a five-week dose ramp-up schedule for Venclexta patients on the Venclexta plus Rituxan arm received six cycles of Venclexta plus Rituxan followed by Venclexta monotherapy for up to two years total.
  • The study included 389 patients with chronic lymphocytic leukemia (CLL), with or without 17p deletion, who had been previously treated with at least one line of therapy.
  • For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology.

Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany

Retrieved on: 
Tuesday, June 1, 2021
South San Francisco, California, Sutro Biopharma, Clinical medicine, Pharmaceutical companies, Medicine, Merck Group, Sutro, Antibody-drug conjugate

Trevor Hallam, Ph.D., Sutro's President of Research and Chief Scientific Officer added, "This partnership demonstrates the combined strength of Sutro and Merck KGaA, Darmstadt, Germany to expand the boundaries of antibody-drug conjugate.

Key Points: 
  • Trevor Hallam, Ph.D., Sutro's President of Research and Chief Scientific Officer added, "This partnership demonstrates the combined strength of Sutro and Merck KGaA, Darmstadt, Germany to expand the boundaries of antibody-drug conjugate.
  • M1231 was generated using Sutro's XpressCF and Sutro's XpressCF+ cell-free protein synthesis and conjugation technologies and includes a Sutro proprietary linker-warhead.
  • Merck KGaA, Darmstadt, Germany will be responsible for drug product, clinical development and, upon regulatory approval, the commercialization of this product candidate.
  • Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

EndBrainCancer Initiative to Host Virtual Worldwide Patient Education Meeting & Event

Retrieved on: 
Monday, May 24, 2021
Health sciences, Life sciences, Drug discovery, Genentech, Hoffmann-La Roche, South San Francisco, California, Therapy, Health sciences, Life sciences, Drug discovery, Genentech, Hoffmann-La Roche, South San Francisco, California, Therapy

SEATTLE, May 24, 2021 /PRNewswire/ -- The EndBrainCancer Initiative (EBCI), today announced its "Know Your Treatment Options" Patient Education Meeting and Event to be held on May 26, 2021 from 11a-1p PT via Zoom.

Key Points: 
  • SEATTLE, May 24, 2021 /PRNewswire/ -- The EndBrainCancer Initiative (EBCI), today announced its "Know Your Treatment Options" Patient Education Meeting and Event to be held on May 26, 2021 from 11a-1p PT via Zoom.
  • "The EndBrainCancer Initiative and I are honored to be able to develop disease educational content and to deliver it to a worldwide audience.
  • We are most grateful to our speakers for taking time out of their busy days to make this patient disease education meeting possible."
  • The EndBrainCancer Initiative would like to thank our sponsors: Karyopharm Therapeutics , Novocure , CURE Media Group , GammaTile Therapy ;with Disease Education Support from Novocure and Genentech .

Ribometrix Wins Triangle Business Journal’s “Best Early-Stage Product Development Company” Award

Retrieved on: 
Thursday, May 20, 2021
Research, Infectious diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Life sciences, Companies, Science and technology in the United States, Genentech, Hoffmann-La Roche, South San Francisco, California, Research Triangle Park, Vertex Pharmaceuticals

b'Ribometrix, Inc., a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced that the company was honored to receive the Triangle Business Journal\xe2\x80\x99s 2021 Life Sciences Award for \xe2\x80\x9cBest Early-Stage Product Development Company.\xe2\x80\x9d\nThe Awards recognize research organizations and individuals in Research Triangle Park (RTP), North Carolina that are making great contributions to the fields of biotechnology and life sciences.

Key Points: 
  • b'Ribometrix, Inc., a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced that the company was honored to receive the Triangle Business Journal\xe2\x80\x99s 2021 Life Sciences Award for \xe2\x80\x9cBest Early-Stage Product Development Company.\xe2\x80\x9d\nThe Awards recognize research organizations and individuals in Research Triangle Park (RTP), North Carolina that are making great contributions to the fields of biotechnology and life sciences.
  • RTP is the largest research park in the United States.\n\xe2\x80\x9cThe Ribometrix team is honored to be recognized among the technology leaders that make the RTP such a thriving hub for innovation,\xe2\x80\x9d said Michael Solomon, Ph.D., chief executive officer of Ribometrix.
  • \xe2\x80\x9cAt Ribometrix, innovation drives our work to deliver a new class of small molecule RNA therapeutics for patients in need.
  • Ribometrix has established collaborations with Genentech, a member of the Roche Group, and Vertex Pharmaceuticals, which leverage Ribometrix\xe2\x80\x99s discovery platform.

Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Friday, May 14, 2021
Cancer, Clinical medicine, Drugs, South San Francisco, California, Sutro Biopharma, Antineoplastic drugs, Hodgkin lymphoma, Multiple myeloma, Orphan drugs, Milatuzumab

STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma.

Key Points: 
  • STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma.
  • STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in October 2018.
  • STRO-002 is a folate receptor alpha (FolR)-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers.
  • The four product candidates above being evaluated in clinical trials resulted from Sutro's XpressCFand XpressCF+ technology platforms.